A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
一项关于MK-1084联合度伐利尤单抗与安慰剂联合度伐利尤单抗在局部晚期、未切除、KRAS G12C突变非小细胞肺癌且接受根治性铂类化放疗后未发生疾病进展的受试者中的III期、随机、双盲、安慰剂和活性对照对比研究(KANDLELIT-015)
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy.
The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Toll Free Number
- 电话号码:1-888-577-8839
- 邮箱:Trialsites@msd.com
学习地点
-
-
Anhui
-
Hefei、Anhui、中国、230031
- 招聘中
- Anhui Provincial Cancer Hospital ( Site 2209)
-
接触:
- Study Coordinator
- 电话号码:+8655165327666
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100730
- 招聘中
- Beijing Peking Union Medical College Hospital ( Site 2220)
-
接触:
- Study Coordinator
- 电话号码:+8601069151188
-
Beijing、Beijing Municipality、中国、100142
- 招聘中
- Beijing Cancer hospital ( Site 2226)
-
接触:
- Study Coordinator
- 电话号码:+86 13901136511
-
Beijing、Beijing Municipality、中国、100142
- 招聘中
- Beijing Cancer hospital ( Site 2217)
-
接触:
- Study Coordinator
- 电话号码:010-88196478
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- 招聘中
- Fujian Cancer Hospital ( Site 2232)
-
接触:
- Study Coordinator
- 电话号码:+8613809500871
-
Xiamen、Fujian、中国、361000
- 招聘中
- Zhongshan Hospital Affiliated to Xiamen University ( Site 2213)
-
接触:
- Study Coordinator
- 电话号码:+8613906036392
-
Xiamen、Fujian、中国、361003
- 招聘中
- The First Affiliated Hospital of Xiamen University. ( Site 2239)
-
接触:
- Study Coordinator
- 电话号码:+8613860458889
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510145
- 招聘中
- The First Affiliated Hospital of Guangzhou Medical University ( Site 2211)
-
接触:
- Study Coordinator
- 电话号码:02083062338
-
-
Guangxi
-
Guilin、Guangxi、中国、541199
- 招聘中
- The Second Affiliated Hospital of Guilin Medical University ( Site 2212)
-
接触:
- Study Coordinator
- 电话号码:07735590035
-
Nanning、Guangxi、中国、530022
- 招聘中
- Guangxi Medical University Cancer Hospital ( Site 2202)
-
接触:
- Study Coordinator
- 电话号码:+867715310045
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050011
- 招聘中
- Fourth Hospital of Hebei Medical University ( Site 2201)
-
接触:
- Study Coordinator
- 电话号码:+8631166696241
-
-
Hubei
-
Wuhan、Hubei、中国、430048
- 招聘中
- Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2206)
-
接触:
- Study Coordinator
- 电话号码:+862783261400
-
Wuhan、Hubei、中国、430070
- 招聘中
- Hubei Cancer Hospital ( Site 2203)
-
接触:
- Study Coordinator
- 电话号码:+862787670275
-
-
Hunan
-
Changsha、Hunan、中国、410011
- 招聘中
- The Second Xiangya Hospital Of Central South University ( Site 2207)
-
接触:
- Study Coordinator
- 电话号码:0731-85295888
-
Changsha、Hunan、中国、410013
- 招聘中
- Hunan Cancer Hospital ( Site 2214)
-
接触:
- Study Coordinator
- 电话号码:0731-89761269
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210000
- 招聘中
- Nanjing Drum Tower Hospital ( Site 2224)
-
接触:
- Study Coordinator
- 电话号码:(86)025-83105910
-
-
Shandong
-
Jinan、Shandong、中国、250117
- 招聘中
- Shandong Cancer Hospital ( Site 2200)
-
接触:
- Study Coordinator
- 电话号码:+8613793150996
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200030
- 招聘中
- Zhongshan Hospital affiliated to Fudan University ( Site 2215)
-
接触:
- Study Coordinator
- 电话号码:+86 13621830381
-
Shanghai、Shanghai Municipality、中国、200032
- 招聘中
- Fudan University Shanghai Cancer Center ( Site 2216)
-
接触:
- Study Coordinator
- 电话号码:8602138196379
-
Shanghai、Shanghai Municipality、中国、200030
- 招聘中
- Shanghai Chest Hospital ( Site 2229)
-
接触:
- Study Coordinator
- 电话号码:+8602122200000
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030013
- 招聘中
- Shanxi Provincial Cancer Hospital ( Site 2227)
-
接触:
- Study Coordinator
- 电话号码:+863514881611
-
-
Sichuan
-
Chengdu、Sichuan、中国、610213
- 招聘中
- Sichuan Cancer hospital. ( Site 2218)
-
接触:
- Study Coordinator
- 电话号码:+8618227667677
-
Chengdu、Sichuan、中国、610041
- 招聘中
- West China Hospital, Sichuan University ( Site 2204)
-
接触:
- Study Coordinator
- 电话号码:+86 28 85422114
-
Chongqing、Sichuan、中国、400030
- 招聘中
- Chongqing University Cancer Hospital ( Site 2236)
-
接触:
- Study Coordinator
- 电话号码:023-65456552
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国、830000
- 招聘中
- Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2225)
-
接触:
- Study Coordinator
- 电话号码:+8609917968111
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310022
- 招聘中
- Zhejiang Cancer Hospital ( Site 2205)
-
接触:
- Study Coordinator
- 电话号码:86057188122482
-
Linhai、Zhejiang、中国、317000
- 招聘中
- Taizhou Hospital of Zhejiang Province ( Site 2223)
-
接触:
- Study Coordinator
- 电话号码:057685199810
-
Wenzhou、Zhejiang、中国、325000
- 招聘中
- The First Affiliated Hospital of Wenzhou Medical University ( Site 2235)
-
接触:
- Study Coordinator
- 电话号码:0577-55578100
-
-
-
-
-
Kyiv、乌克兰、03057
- 招聘中
- Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 2005)
-
接触:
- Study Coordinator
- 电话号码:+380669472333
-
Kyiv、乌克兰、03680
- 招聘中
- Shalimov Institute of Surgery and Transplantation ( Site 2003)
-
接触:
- Study Coordinator
- 电话号码:+380933333911
-
-
Chernivetska Oblast
-
Chernivtsi、Chernivetska Oblast、乌克兰、58013
- 招聘中
- Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 2002)
-
接触:
- Study Coordinator
- 电话号码:+380505144910
-
-
Dnipropetrovsk Oblast
-
Kryvyi Rih、Dnipropetrovsk Oblast、乌克兰、50000
- 招聘中
- Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 2012)
-
接触:
- Study Coordinator
- 电话号码:+380973567855
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk、Ivano-Frankivsk Oblast、乌克兰、76018
- 招聘中
- Communal Non-Commercial Enterprise "Prykarpatski Clinical Oncological Center" of Ivano-Frankivsk Reg ( Site 2006)
-
接触:
- Study Coordinator
- 电话号码:+380342540325
-
-
Kirovohrad Oblast
-
Kropyvnytskyi、Kirovohrad Oblast、乌克兰、25006
- 招聘中
- Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 2013)
-
接触:
- Study Coordinator
- 电话号码:+380969680396
-
Kropyvnytskyi、Kirovohrad Oblast、乌克兰、25011
- 招聘中
- Ukrainian Center of Tomotherapy ( Site 2014)
-
接触:
- Study Coordinator
- 电话号码:+380676239652
-
-
Kyivska Oblast
-
Kyiv、Kyivska Oblast、乌克兰、03115
- 招聘中
- Kyiv City Clinical Oncology Center ( Site 2015)
-
接触:
- Study Coordinator
- 电话号码:+380672455533
-
-
Lviv Oblast
-
Lviv、Lviv Oblast、乌克兰、79031
- 招聘中
- Lviv Oncology Regional Treatment and Diagnostic Center ( Site 2009)
-
接触:
- Study Coordinator
- 电话号码:+380975814015
-
Lviv、Lviv Oblast、乌克兰、79059
- 招聘中
- Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 2000)
-
接触:
- Study Coordinator
- 电话号码:+380977453295
-
-
Odesa Oblast
-
Odesa、Odesa Oblast、乌克兰、65025
- 招聘中
- Municipal non-profit enterprise'Odesa Regional Clinical Hospital'of Odesa Regional Council ( Site 2011)
-
接触:
- Study Coordinator
- 电话号码:+380972147211
-
-
Rivne Oblast
-
Rivne、Rivne Oblast、乌克兰、33010
- 招聘中
- ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2001)
-
接触:
- Study Coordinator
- 电话号码:+380971921000
-
-
Vinnytsia Oblast
-
Vinnytsia、Vinnytsia Oblast、乌克兰、21029
- 招聘中
- Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 2004)
-
接触:
- Study Coordinator
- 电话号码:+380432511160
-
-
Volyn Oblast
-
Lutsk、Volyn Oblast、乌克兰、43018
- 招聘中
- Volyn Regional Clinical Hospital ( Site 2010)
-
接触:
- Study Coordinator
- 电话号码:+380503782998
-
-
-
-
-
New Taipei City、台湾、23561
- 招聘中
- Taipei Medical University Shuang Ho Hospital ( Site 2612)
-
接触:
- Study Coordinator
- 电话号码:+886-970-747-515
-
Tainan、台湾、704
- 招聘中
- National Cheng Kung University Hospital ( Site 2601)
-
接触:
- Study Coordinator
- 电话号码:+886-6-2353535#3120
-
Taipei、台湾、10449
- 招聘中
- Mackay Memorial Hospital ( Site 2611)
-
接触:
- Study Coordinator
- 电话号码:+886-2543-3535
-
Taipei、台湾、114
- 招聘中
- Tri-Service General Hospital ( Site 2608)
-
接触:
- Study Coordinator
- 电话号码:+886287923311
-
Taipei、台湾、106
- 招聘中
- National Taiwan University Cancer Center (NTUCC) ( Site 2610)
-
接触:
- Study Coordinator
- 电话号码:+886-2-2312-3456
-
-
-
-
-
Adana、土耳其(türkiye)、01140
- 招聘中
- Adana Medical Park Seyhan Hastanesi ( Site 1910)
-
接触:
- Study Coordinator
- 电话号码:00904444484
-
Adana、土耳其(türkiye)、01250
- 招聘中
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1903)
-
接触:
- Study Coordinator
- 电话号码:905353067506
-
Ankara、土耳其(türkiye)、06230
- 招聘中
- Hacettepe Universite Hastaneleri ( Site 1900)
-
接触:
- Study Coordinator
- 电话号码:+903123052841
-
Ankara、土耳其(türkiye)、06680
- 招聘中
- Liv Hospital Ankara ( Site 1911)
-
接触:
- Study Coordinator
- 电话号码:+90 5520045315
-
Kayseri、土耳其(türkiye)、38039
- 招聘中
- Erciyes University ( Site 1904)
-
接触:
- Study Coordinator
- 电话号码:+90 207 666 6270
-
Mersin、土耳其(türkiye)、33240
- 招聘中
- Mersin Sehir Eğitim ve Araştırma Hastanesi. ( Site 1907)
-
接触:
- Study Coordinator
- 电话号码:903242251000
-
Rize、土耳其(türkiye)、53020
- 招聘中
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 1908)
-
接触:
- Study Coordinator
- 电话号码:+905069939926
-
-
Ankara
-
Çankaya、Ankara、土耳其(türkiye)、6800
- 招聘中
- Ankara Bilkent Şehir Hastanesi. ( Site 1906)
-
接触:
- Study Coordinator
- 电话号码:903125526000
-
-
Istanbul
-
Kartal、Istanbul、土耳其(türkiye)、34890
- 招聘中
- KARTAL DR. LÜTF KIRDAR ETM VE ARATIRMA HASTANES. ( Site 1909)
-
接触:
- Study Coordinator
- 电话号码:+902164413900
-
-
-
-
Ceará
-
Fortaleza、Ceará、巴西、60336-232
- 招聘中
- CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 0406)
-
接触:
- Study Coordinator
- 电话号码:+55 85 32865934
-
-
Espírito Santo
-
Vitória、Espírito Santo、巴西、29043-260
- 招聘中
- AFECC ASSOCIACAO FEMININA EDUCACAO COMBATE CANCER ( Site 0416)
-
接触:
- Study Coordinator
- 电话号码:+5527998469004
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90020-090
- 招聘中
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0415)
-
接触:
- Study Coordinator
- 电话号码:+555132148107
-
-
Santa Catarina
-
Florianópolis、Santa Catarina、巴西、88034-000
- 招聘中
- CEPON ( Site 0413)
-
接触:
- Study Coordinator
- 电话号码:+554833311553
-
-
São Paulo
-
Barretos、São Paulo、巴西、14784-400
- 招聘中
- Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0401)
-
接触:
- Study Coordinator
- 电话号码:+551733216638
-
-
-
-
Attica
-
Athens、Attica、希腊、151 25
- 招聘中
- Athens Medical Center ( Site 1201)
-
接触:
- Study Coordinator
- 电话号码:+306986817837
-
Athens、Attica、希腊、115 28
- 招聘中
- ALEXANDRA General Hospital of Athens ( Site 1200)
-
接触:
- Study Coordinator
- 电话号码:+306934137080
-
Athens、Attica、希腊、115 27
- 招聘中
- THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 1205)
-
接触:
- Study Coordinator
- 电话号码:+302107700220
-
Piraeus、Attica、希腊、185 37
- 招聘中
- Metaxa Cancer Hospital of Piraeus ( Site 1203)
-
接触:
- Study Coordinator
- 电话号码:+306940583449
-
-
East Macedonia and Thrace
-
Alexandroupoli、East Macedonia and Thrace、希腊、681 00
- 招聘中
- University General Hospital of Alexandroupoli ( Site 1206)
-
接触:
- Study Coordinator
- 电话号码:+306973489404
-
-
-
-
-
Hamburg、德国、22087
- 招聘中
- Katholisches Marienkrankenhaus gGmbH ( Site 1101)
-
接触:
- Study Coordinator
- 电话号码:+494025460
-
Hamburg、德国、20246
- 招聘中
- Universitaetsklinikum Hamburg-Eppendorf ( Site 1111)
-
接触:
- Study Coordinator
- 电话号码:+4940741057118
-
-
North Rhine-Westphalia
-
Münster、North Rhine-Westphalia、德国、48153
- 招聘中
- Gemeinschaftspraxis für Hämatologie und Onkologie Münster ( Site 1108)
-
接触:
- Study Coordinator
- 电话号码:+492519764537
-
-
-
-
Emilia-Romagna
-
Meldola、Emilia-Romagna、意大利、47014
- 招聘中
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1403)
-
接触:
- Study Coordinator
- 电话号码:+390543739100
-
-
Lazio
-
Rome、Lazio、意大利、00168
- 招聘中
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1401)
-
接触:
- Study Coordinator
- 电话号码:+390630155202
-
Rome、Lazio、意大利、00144
- 招聘中
- Istituto Nazionale Tumori Regina Elena ( Site 1404)
-
接触:
- Study Coordinator
- 电话号码:+3906544289247
-
-
Lombardy
-
Milan、Lombardy、意大利、20133
- 招聘中
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1400)
-
接触:
- Study Coordinator
- 电话号码:+390223903831
-
-
-
-
Gunma
-
Ōta、Gunma、日本、373-8550
- 招聘中
- Gunma Prefectural Cancer Center ( Site 2302)
-
接触:
- Study Coordinator
- 电话号码:+81-276-38-0771
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、003-0804
- 招聘中
- National Hospital Organization Hokkaido Cancer Center ( Site 2312)
-
接触:
- Study Coordinator
- 电话号码:+81-11-811-9111
-
-
Hyōgo
-
Kobe、Hyōgo、日本、650-0046
- 招聘中
- Kobe Minimally Invasive Cancer Center ( Site 2306)
-
接触:
- Study Coordinator
- 电话号码:+81-78-304-4100
-
-
Mie-ken
-
Matsusaka、Mie-ken、日本、515-8544
- 招聘中
- Saiseikai Matsusaka Municipal Hospital ( Site 2311)
-
接触:
- Study Coordinator
- 电话号码:+81-598-23-1515
-
-
Miyagi
-
Sendai、Miyagi、日本、981-0914
- 招聘中
- Sendai Kousei Hospital ( Site 2300)
-
接触:
- Study Coordinator
- 电话号码:+81-22-728-8000
-
-
Tochigi
-
Shimotsugagun、Tochigi、日本、321-0293
- 招聘中
- Dokkyo Medical University Hospital ( Site 2301)
-
接触:
- Study Coordinator
- 电话号码:+81-282-86-1111
-
-
-
-
Gironde
-
Pessac、Gironde、法国、33600
- 招聘中
- CHU Bordeaux Haut-Leveque ( Site 1005)
-
接触:
- Study Coordinator
- 电话号码:+33556795679
-
-
Nord
-
Valenciennes、Nord、法国、59300
- 招聘中
- Clinique Teissier Groupe ( Site 1006)
-
接触:
- Study Coordinator
- 电话号码:+33327142434
-
-
-
-
Podkarpackie Voivodeship
-
Przemyśl、Podkarpackie Voivodeship、波兰、37-700
- 招聘中
- Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1602)
-
接触:
- Study Coordinator
- 电话号码:+48166775000
-
-
-
-
New South Wales
-
Frenchs Forest、New South Wales、澳大利亚、2086
- 招聘中
- Northern Beaches Hospital ( Site 2401)
-
接触:
- Study Coordinator
- 电话号码:+61291055090
-
-
Queensland
-
South Brisbane、Queensland、澳大利亚、4101
- 招聘中
- Mater Misericordiae Limited ( Site 2402)
-
接触:
- Study Coordinator
- 电话号码:+61731762111
-
Woolloongabba、Queensland、澳大利亚、4102
- 招聘中
- Princess Alexandra Hospital ( Site 2406)
-
接触:
- Study Coordinator
- 电话号码:+61731766577
-
-
Victoria
-
Frankston、Victoria、澳大利亚、3199
- 招聘中
- Frankston Hospital ( Site 2403)
-
接触:
- Study Coordinator
- 电话号码:+61 3 9784 7777
-
-
-
-
Georgia
-
Atlanta、Georgia、美国、30318
- 招聘中
- Piedmont Atlanta Hospital ( Site 0121)
-
接触:
- Study Coordinator
- 电话号码:999-999-9999
-
Savannah、Georgia、美国、31404
- 招聘中
- Low Country Cancer Care ( Site 0155)
-
接触:
- Study Coordinator
- 电话号码:912-692-2000
-
-
Illinois
-
Lisle、Illinois、美国、60532
- 招聘中
- Duly Healthcare ( Site 0158)
-
接触:
- Study Coordinator
- 电话号码:630-545-7760
-
-
Nebraska
-
Lincoln、Nebraska、美国、68506
- 招聘中
- NHO Revive Research Institute LLC ( Site 0118)
-
接触:
- Study Coordinator
- 电话号码:402-484-4900
-
-
New Jersey
-
New Brunswick、New Jersey、美国、08901
- 招聘中
- Rutgers Cancer Institute of New Jersey ( Site 0100)
-
接触:
- Study Coordinator
- 电话号码:732-395-8823
-
-
New York
-
Albany、New York、美国、12206
- 招聘中
- New York Oncology Hematology P.C ( Site 9000)
-
接触:
- Study Coordinator
- 电话号码:518-489-0044
-
-
North Carolina
-
Raleigh、North Carolina、美国、27610
- 招聘中
- WakeMed Raleigh Campus ( Site 0144)
-
接触:
- Study Coordinator
- 电话号码:919-350-2873
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Virginia Cancer Specialists ( Site 0114)
-
接触:
- Study Coordinator
- 电话号码:703-208-3110
-
-
-
-
-
Cardiff、英国、CF14 2TL
- 招聘中
- Velindre Cancer Centre ( Site 2104)
-
接触:
- Study Coordinator
- 电话号码:029 2061 5888
-
Leeds、英国、LS9 7TF
- 招聘中
- St James's University Hospital ( Site 2100)
-
接触:
- Study Coordinator
- 电话号码:+441132068436
-
-
-
-
-
Groningen、荷兰、9713 GZ
- 招聘中
- University Medical Center Groningen ( Site 1505)
-
接触:
- Study Coordinator
- 电话号码:+31503614679
-
-
Gelderland
-
Nijmegen、Gelderland、荷兰、6525 GA
- 招聘中
- Radboudumc ( Site 1504)
-
接触:
- Study Coordinator
- 电话号码:+ 31243610353
-
-
Overijssel
-
Hengelo、Overijssel、荷兰、7555 DL
- 招聘中
- Ziekenhuis Groep Twente, locatie Hengelo ( Site 1500)
-
接触:
- Study Coordinator
- 电话号码:0031887083454
-
-
South Holland
-
Leiden、South Holland、荷兰、2333 ZA
- 招聘中
- Leids Universitair Medisch Centrum ( Site 1503)
-
接触:
- Study Coordinator
- 电话号码:+31715566376
-
-
-
-
-
Barcelona、西班牙、08035
- 招聘中
- Hospital Universitari Vall d'Hebron ( Site 1800)
-
接触:
- Study Coordinator
- 电话号码:+34932746000
-
Madrid、西班牙、28040
- 招聘中
- Hospital Clinico San Carlos ( Site 1810)
-
接触:
- Study Coordinator
- 电话号码:+34913303000x484835
-
Madrid、西班牙、28046
- 招聘中
- Hospital Universitario La Paz ( Site 1808)
-
接触:
- Study Coordinator
- 电话号码:+34917277516
-
Madrid、西班牙、28007
- 招聘中
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1803)
-
接触:
- Study Coordinator
- 电话号码:+34915868115
-
Seville、西班牙、41007
- 招聘中
- Hospital Universitario Virgen Macarena ( Site 1805)
-
接触:
- Study Coordinator
- 电话号码:+34955008000
-
-
Gerona
-
Girona、Gerona、西班牙、17007
- 招聘中
- Institut Català d'Oncologia (ICO) - Girona-Oncología Médica ( Site 1807)
-
接触:
- Study Coordinator
- 电话号码:+34972225834
-
-
Valenciana, Comunitat
-
Valencia、Valenciana, Comunitat、西班牙、46009
- 招聘中
- Fundación Instituto Valenciano de Oncología ( Site 1809)
-
接触:
- Study Coordinator
- 电话号码:+34961114230
-
-
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires、Buenos Aires、阿根廷、C1430EGF
- 招聘中
- Clinica Adventista Belgrano ( Site 0304)
-
接触:
- Study Coordinator
- 电话号码:+541132682903
-
Ciudad Autonoma de Buenos Aires、Buenos Aires、阿根廷、C1199ABB
- 招聘中
- Hospital Italiano de Buenos Aires. ( Site 0300)
-
接触:
- Study Coordinator
- 电话号码:+541149590200
-
Ciudad Autonoma de Buenos Aires.、Buenos Aires、阿根廷、C1426ANZ
- 招聘中
- Instituto Alexander Fleming ( Site 0301)
-
接触:
- Study Coordinator
- 电话号码:+541132218900
-
Mar del Plata、Buenos Aires、阿根廷、B7600FZO
- 招聘中
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0303)
-
接触:
- Study Coordinator
- 电话号码:+542234963223
-
-
Buenos Aires F.D.
-
Buenos Aires、Buenos Aires F.D.、阿根廷、C1280AEB
- 招聘中
- Hospital Britanico de Buenos Aires ( Site 0305)
-
接触:
- Study Coordinator
- 电话号码:+541127698713
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、S2000DSV
- 招聘中
- Sanatorio Parque ( Site 0302)
-
接触:
- Study Coordinator
- 电话号码:54 341 40200222
-
-
-
-
-
Seoul、韩国、03722
- 招聘中
- Severance Hospital, Yonsei University Health System ( Site 2501)
-
接触:
- Study Coordinator
- 电话号码:82-2-2228-0831
-
Seoul、韩国、05505
- 招聘中
- Asan Medical Center ( Site 2500)
-
接触:
- Study Coordinator
- 电话号码:+82230103214
-
-
Kyonggi-do
-
Goyang-si、Kyonggi-do、韩国、10408
- 招聘中
- National Cancer Center ( Site 2505)
-
接触:
- Study Coordinator
- 电话号码:+82319201694
-
Suwon、Kyonggi-do、韩国、16499
- 招聘中
- Ajou University Hospital ( Site 2504)
-
接触:
- Study Coordinator
- 电话号码:+8216886114
-
-
North Chungcheong
-
Cheongju-si、North Chungcheong、韩国、28644
- 招聘中
- Chungbuk National University Hospital ( Site 2502)
-
接触:
- Study Coordinator
- 电话号码:+82432696015
-
-
Taegu-Kwangyokshi
-
Daegu、Taegu-Kwangyokshi、韩国、42601
- 招聘中
- Keimyung University Dongsan Hospital ( Site 2503)
-
接触:
- Study Coordinator
- 电话号码:+82532586671
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histological or cytological diagnosis of locally advanced, unresected Stage II (node-positive) to III non-small cell lung cancer (NSCLC) with predominantly nonsquamous histology.
- Has completed definitive platinum-based concurrent chemoradiotherapy (CCRT) prior to enrollment, without disease progression.
- Has provided a tumor tissue sample for central laboratory testing of Kirsten rat sarcoma G12C (KRAS G12C) status, programmed cell death ligand 1 (PD-L1) status, and biomarker research.
- Tumor tissue sample has a demonstrated presence of KRAS G12C mutation and an evaluable PD-L1 status result.
- If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART).
- If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy.
- If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
- Has a body weight ≥35 kg.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a diagnosis of small cell lung cancer or mixed tumors with small cell elements.
- Has a gastrointestinal disorder affecting absorption or is unable to swallow orally administered medication.
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease.
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
- Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
- Has received prior treatment (other than definitive CCRT) for NSCLC.
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- Has a history of, or has current, (noninfectious) pneumonitis/interstitial lung disease that required/requires steroids.
- Has an active infection requiring systemic therapy.
- Has a history of stem cell/solid organ transplant.
- Has not adequately recovered from major surgery or has ongoing surgical complications.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Calderasib + Durvalumab
Participants will receive calderasib and durvalumab. |
Tablet for oral administration.
其他名称:
Solution for intravenous (IV) infusion.
其他名称:
|
|
有源比较器:Placebo + Durvalumab
Participants will receive placebo to calderasib and durvalumab. |
Solution for intravenous (IV) infusion.
其他名称:
Placebo to MK-1084. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS)
大体时间:Up to approximately 6 years
|
PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. |
Up to approximately 6 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:Up to approximately 9 years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 9 years
|
|
Number of Participants Who Experience an Adverse Events (AEs)
大体时间:Up to approximately 9 years
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be presented. |
Up to approximately 9 years
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
大体时间:Up to approximately 9 years
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 9 years
|
|
Objective Response Rate (ORR)
大体时间:Up to approximately 9 years
|
ORR is defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented. |
Up to approximately 9 years
|
|
Duration of Response (DOR)
大体时间:Up to approximately 9 years
|
For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. |
Up to approximately 9 years
|
|
Distant Metastasis-Free Survival (DMFS)
大体时间:Up to approximately 9 years
|
DMFS is defined as the time from randomization to the first diagnosis of a distant metastasis as assessed by investigator, or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread beyond the original (primary) tumor/regional metastases to distant organs or distant lymph nodes. |
Up to approximately 9 years
|
|
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) (Items 29 & 30) Combined Score
大体时间:Baseline and up to approximately 9 years
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented. |
Baseline and up to approximately 9 years
|
|
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Combined Score
大体时间:Baseline and up to approximately 9 years
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented. |
Baseline and up to approximately 9 years
|
|
Change from Baseline in Role Functioning (EORTC QLQ-C30 Items 6 & 7) Combined Score
大体时间:Baseline and up to approximately 9 years
|
The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported. |
Baseline and up to approximately 9 years
|
合作者和调查者
调查人员
- 研究主任:Medical Director、Merck Sharp & Dohme LLC
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 1084-015
- 2025-522038-29-00 (注册表标识符:EU CT)
- U1111-1321-6971 (注册表标识符:UTN)
- MK-1084-015 (其他标识符:MSD)
- KANDLELIT-015 (其他标识符:MSD)
- jRCT2021260021 (注册表标识符:jRCT)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.